• vcard
  • Education
    • J.D., cum laude, University of Ottawa Faculty of Law, 1994, Common Law
    • Ph.D., McMaster University, 1992, Medical Science - Neuroscience; Awarded over 20 post-graduate academic prizes, awards, and scholarships
    • B.Sc., with honors, Queen's University, 1984, Life Sciences
  • Bar Jurisdictions
    • Massachusetts, 1995
    • Admitted to practice before the United States Patent and Trademark Office
Dr. Michel Morency provides legal counsel to many sectors of the biotechnology, pharmaceutical, life sciences, and medical devices business community. This includes top–tier pharmaceutical companies, public and private companies, and start-up companies. He advises clients on the creation and development of patent portfolios, collaborative research, licensing of technology and enforcement of their intellectual property rights. He also provides clients with patent invalidity, freedom to operate, and non-infringement opinions.

Mike helps clients raise money through venture capital and other financial transactions, in addition to monetizing their intellectual property by out-licensing, or selling future royalties and intellectual property rights. He frequently performs due diligence investigations for private and public financings and mergers and acquisitions transactions for clients and in various industries.

His legal experience encompasses numerous technologies, including:
  • Neurobiology, neurodegenerative disorders
  • Stem cell and transgenic technologies
  • Immunology and vaccine technologies
  • Novel antibiotics
  • Cancer therapeutics
  • Tissue and organ regeneration
  • Blood cells and blood products
  • Drug delivery and discovery
  • Gene therapy
  • Genomics
  • Proteomics
  • Nanotechnologies
  • Antioxidants
  • Nutraceuticals and dietary supplement technologies
  • Medical devices
Mergers & Acquisitions
  • Represented a privately-held specialty pharmaceutical company in an acquisition by a publicly-traded NASDAQ pharmaceutical company for $125M USD plus milestones  
  • Represented a privately-held biomedical cancer therapeutic company in an acquisition/asset purchase by a publicly-traded NASDAQ biotech company for $55.3M USD  
  • Represented a publicly-traded NASDAQ regenerative medicine company in the merger with two privately-held biotech companies to form a new publicly-traded NASDAQ regenerative medicine company  
Strategic Collaborations/Licensing  
  • Represented a privately-held biomedical diagnostic company, in a multi-year, worldwide Distribution Agreement with a Fortune 500 healthcare company  
  • Represented a publicly-traded NASDAQ genomics company in a Collaboration Agreement with a Fortune 500 pharmaceutical company worth over $1.5B USD  
  • Represented a privately-held biotech regenerative medicine company in an Exclusive Licensing Agreement with a Fortune 500 pharmaceutical company worth over $125M USD, with $15 million USD upon signing
  • Represented a subsidiary of a publicly-traded TYO pharmaceutical company in a Sponsored Research Agreement and an Exclusive License Agreement with an American university  
Initial Public Offerings (IPOs)  
  • Represented a privately-held specialty pharmaceutical company in an IPO on NASDAQ for $70M USD  
  • Represented the underwriters in the IPO of a privately-held molecular diagnostic company on NASDAQ for $82.5M USD  
  • Represented the underwriters in the IPO of a privately-held biotechnology company on TSX for $42.4M CDN, representing the largest Life Sciences IPO in Canada at the time
text icon Publications & Presentations
Featured in Boston Business Journal
March 24, 2017
text icon Publications & Presentations
The Importance of Intellectual Property in Biotechnology
Guest lecturer, Brown University
Fall 2016
text icon Publications & Presentations
Guest lecturer, Various Intellectual Property Topics
2013 - 2015